What is the stock price of T2 Biosystems (TTOO) today?
Mar 18, 2022 · Researching T2 Biosystems (NASDAQ:TTOO) stock? View TTOO's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.
Where can I buy TTOO shares?
Apr 22, 2022 · TTOO | Complete T2 Biosystems Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
What does TTOO's asset turnover ratio rank among medical equipment stocks?
Real time T2 Biosystems (TTOO) stock price quote, stock graph, news & analysis.
How does TTOO's equity multiplier compare to other US stocks?
Apr 08, 2022 · Analyst Forecast. According to 10 analysts, the average rating for TTOO stock is "Buy." The 12-month stock price forecast is 1.07, which is …
Is TTOO a good stock to buy?
The consensus among 1 Wall Street analyst covering (NASDAQ: TTOO) stock is to Strong Buy TTOO stock.
Will T2 Biosystems stock go up?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for T2 Biosystems Inc have a median target of 1.00, with a high estimate of 1.50 and a low estimate of 0.70. The median estimate represents a +101.41% increase from the last price of 0.50.
What does T2 Biosystems do?
T2 Biosystems, Inc. is an in-vitro diagnostics company. The Company is focused on rapid detection of sepsis-causing pathogens and antibiotic resistance genes.
What does TTOO company do?
T2 Biosystems Inc (NASDAQ:TTOO) engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types.
Where is T2 Biosystems located?
Overview Suggest EditTypePublicHQLexington, MA, USMapWebsitet2biosystems.comEmployee Ratings3MoreOverall CultureFMore1 more row
How many employees does T2 Biosystems have?
182 totalCompany Description: T2 Biosystems, Inc. is located in Lexington, MA, United States and is part of the Medical Equipment and Supplies Manufacturing Industry. T2 Biosystems, Inc. has 182 total employees across all of its locations and generates $28.06 million in sales (USD)....Just $139.99 *YearRevenue202018.133 more rows
Is T2 Biosystems a buy right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 3 bu...
How has T2 Biosystems' stock been impacted by COVID-19 (Coronavirus)?
T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health O...
Are investors shorting T2 Biosystems?
T2 Biosystems saw a increase in short interest in February. As of February 28th, there was short interest totaling 7,160,000 shares, an increase of...
When is T2 Biosystems' next earnings date?
T2 Biosystems is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for T2 Biosys...
How were T2 Biosystems' earnings last quarter?
T2 Biosystems, Inc. (NASDAQ:TTOO) issued its earnings results on Wednesday, February, 16th. The medical equipment provider reported ($0.07) EPS for...
What guidance has T2 Biosystems issued on next quarter's earnings?
T2 Biosystems updated its FY 2022 earnings guidance on Thursday, March, 10th. The company provided earnings per share guidance of for the period. T...
What price target have analysts set for TTOO?
3 equities research analysts have issued 12 month price objectives for T2 Biosystems' stock. Their forecasts range from $0.70 to $3.00. On average,...
Who are T2 Biosystems' key executives?
T2 Biosystems' management team includes the following people: John J. Sperzel , Chairman, President & Chief Executive Officer Alec Barclay , Chi...
What is John McDonough's approval rating as T2 Biosystems' CEO?
36 employees have rated T2 Biosystems CEO John McDonough on Glassdoor.com . John McDonough has an approval rating of 54% among T2 Biosystems' empl...
About T2 Biosystems
T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types.
Recently Viewed Tickers
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" T2 Biosystems stock. View analyst ratings for T2 Biosystems or view top-rated stocks.
T2 Biosystems Inc
Visit a quote page and your recently viewed tickers will be displayed here.
Hot Penny Stocks to Add to Your List With High Market Volatility
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types.
T2 Biosystems Announces Fourth Quarter & Full Year 2021 Financial Results
Can these penny stocks continue to climb in February? The post Hot Penny Stocks to Add to Your List With High Market Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
T2 Biosystems Announces Commercial Expansion Through Distributors in Norway, Finland and Türkiye
Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
LEXINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive d...
T2 Biosystems to Report Fourth Quarter and Full Year 2021 Financial Results on February 17, 2022
LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the successful amendment and extension...
T2 Biosystems Reports Granting of Inducement Award
LEXINGTON, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results ...
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results
LEXINGTON, Mass., Feb. 04, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to eig...
Component Grades
LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and op...
TTOO POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
TTOO Stock Summary
Value is the dimension where TTOO ranks best; there it ranks ahead of 59.96% of US stocks.
TTOO Valuation Summary
T2 Biosystems Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 1.45% of US listed stocks.
TTOO Growth Metrics
In comparison to the median Healthcare stock, TTOO's EV/EBIT ratio is 115.36% lower, now standing at -4.5.
TTOO's Quality Factors
The 5 year net income to common stockholders growth rate now stands at -22.27%.
Latest TTOO News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Signals & Forecast
Below are the latest news stories about T2 Biosystems Inc that investors may wish to consider to help them evaluate TTOO as an investment opportunity.
Support, Risk & Stop-loss
The T2 Biosystems stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Is T2 Biosystems stock A Buy?
T2 Biosystems finds support from accumulated volume at $0.44 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in T2 Biosystems
Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term.
About T2 Biosystems
In the last 100 trades there were 10.54 million shares bought and 2.49 million shares sold. The last trade was done 4 days ago by Barclay Alec who sold 10 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
